How embracing 'moments of pause' can help us when we're bored
Before you reach for your phone to scroll or check an email, it's worth considering the benefits of sitting with it.
What we do with this feeling is important, according to Michelle Kennedy, a mental health researcher on Kabi Kabi lands, on the Sunshine Coast.
"Society has almost conditioned us that it's indulgent to be bored," she says.
"[But] eliminating the state of boredom deprives us of a simple and natural way to reset our nervous system."
So how can we embrace boredom, and what are some of the other benefits of doing so?
Officially, boredom is defined as difficulty maintaining attention or interest in a current activity.
Dr Kennedy says the fast-paced world we live in means some of us may not be allowing ourselves to fully experience moments of boredom.
"It's so overstimulated, we are taking in so much information," she says.
"Say we finish a task earlier than we anticipate, rather than just sitting there allowing us just to be in that moment, often we go 'Ok what else can I do to fill this space?'
"[Or] you're watching a movie and all of a sudden it hits a low spot [and] you're going 'OK, this isn't really capturing my attention', so then your attention is turned to other things."
Mandie Shean says our obsession with technology is exacerbating the situation.
The adjunct lecturer in education at Edith Cowan University believes some of us are not good at handling feelings "of being uncomfortable".
Dr Kennedy says reframing these moments of boredom as "pauses" could help us incorporate them into our day in a positive way.
"Embracing that moment, and … just making time for that pause," she says.
"Let's all take the dog for a walk or just sit out the back and have a chat.
She says "starting small" will help us understand the benefits and then to gradually build more of that space into our day.
Dr Kennedy says as adults we are often juggling work and family life.
So if we have time between activities, we may be on our screens constantly organising, updating, or scrolling to simply stay occupied.
"What we're doing is we're overloading our neural pathways," Dr Kennedy says.
"When that nervous system is activated for too long … our system becomes overwhelmed.
"So, it keeps us in this heightened state of arousal, which, long term can develop those early symptoms of anxiety."
Dragan Rangelov, a psychology and cognitive neuroscience lecturer from Swinburne University of Technology says allowing ourselves to be bored (and not on screens) may reduce the activation of our sympathetic nervous system and "produce overall greater wellbeing".
"It kind of flushes out this sort of sensory overload and possible negative consequences of it," Dr Rangelov says.
Our experts say there are a few ways we can let ourselves experience boredom.
Dr Rangelov says one method is mindfulness training or simply "sitting there and soaking the boredom in".
"Mindfulness is essentially just focusing on yourself," he says.
"There's mindfulness about your physical sort of sensations, how your breath is looking, what's your heartbeat?
"There's also mindfulness about your psychological processes, whether you are anxious, whether you're agitated."
This practice can help with emotional regulation and can lead to insights about your emotional responses to external events.
Dr Shean says another way of embracing pauses or boredom is to engage in an activity.
"It takes 15 minutes to get engaged in any task," Dr Shean says.
"So, you can set a timer, the Pomodoro timer is a really good thing when you're bored.
"It breaks up an activity into 25-minute intervals and then you get a break and it makes you engage even when you feel bored."
She says it's also important to remember that just because a task seems boring doesn't mean it's not beneficial.
"Doing my PhD was really boring in parts, learning my tables was boring, and cleaning the house was boring," she says.
"And maybe for you, learning French or whatever it might be, it can be boring.
"But some of those things are amazing and they're really good choices and you need to sort of hold space for those uncomfortable feelings in the middle of it."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
20 minutes ago
- ABC News
Improvements in treatment for Parkinson's patients
There's good news in the search for better treatment options for those living with Parkinson's disease. Researchers from the University of South Australia have developed a long-acting injection that could one day replace daily oral medications. The injection will still need to undergo a series of testing, but scientists are hopeful the treatment could eventually open more possibilities for treating a range of other chronic illnesses.

News.com.au
28 minutes ago
- News.com.au
Health Check: Imugene goes to the well after reporting more blood cancer ‘cures'
Imugene reports two more 'complete responders' in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk Compumedics shares vault 24% after full-year update Imugene (ASX:IMU) will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more 'complete responses' in its phase 1b study. There's also the matter of cash, with Imugene shares this morning entering trading halt amidst a capital raising reportedly targeting $35 million. The trial is testing the company's CD-19 Car-T therapy on patients with relapsed diffuse large B-cell lymphoma. This is an especially aggressive blood cancer and these patients have failed multiple therapies. The company reports that of five further patients evaluated, two showed a 'complete response'. A complete response is the disappearance of all cancer signs – a.k.a. a cure. A further five showed a 'partial response' – at least a 50% cancer cell reduction. This takes the total number of complete responses to six and partial responses to three, out of 12 patients. The effect has endured for at least 60 days, with the first patient treated remaining cancer free at the 15-month mark. 'Allo 'allo, we're on to something If approved, Azer-cel would be the first off-the-shelf Car-T therapy using donor cells rather than the patients' own material. This is the allogeneic (allo), as opposed to autologous, method. Car-T therapies involve taking T-cells out of blood and tricking them up with agents that bolster their cancer-busting abilities. They are then re-introduced into the bloodstream. The re-engineered cells pursue a target, in this case the CD-19 protein expressed by blood cancers. Next stop: FDA The ongoing study is being carried out at 13 US sites and the first of five planned local sites. The company in February treated the first Australian participant, at Sydney's Royal Prince Alfred Hospital. The subjects were dosed with Azercel, combined alongside chemotherapy and the immunity agent interleukin 2. Imugene plans to meet with the US Food & Drug Administration (FDA) in the December quarter, to discuss a pivotal registration study. As of the end of March, Imugene held cash of $36 million. Drug development is hideously expensive and the last raising is never the final one, and what better time to go to the well than after positive clinical results? Imugene raised $53 million in 2023 and $80 million in 2020 and this year entered into a $20 million convertible note issue. Imugene shares have lost 68% year to date, adjusting for a share consolidation that reduced its 7.46 billion shares on issue to a more respectable 219 million. Clever Culture bulks up with fat-busting drug maker Clever Culture Systems (ASX:CC5) has signed up Big Pharma Novo Nordisk for one of its automated agar plate reading devices to monitor ultra-clean drug making facilities. The maker of the weight loss and diabetes drugs Ozempic and Wegovy, Novo Nordisk will acquire and appraise one of Clever Culture's AI-enabled device APAS Independence units, in view of a full global rollout across its facilities. The AI-enabled APAS Independence devices automatically read the hundreds of agar plates required to ensure that pathogens don't enter aseptic facilities. The units can manage 200 plates per hour, freeing up microbiologists to focus on the minority of plates that read positive. To date Clever Culture has focused on 90 millimetre 'settle' plates that are left open, to absorb any nasties in the room. A tweaked APAS also will read 55mm 'contact' plates, which are dabbed on surfaces, such as a gown or gloved fingertips. Nova Nordisk will assess both settle and contact plate modules. Courting Big Pharma Clever Culture CEO Brent Barnes says the 'milestone' deal aligns with the company's focus on the big drug makers, most of which have centres to appraise new products. To date Clever Culture also sold the devices to Astrazeneca, Bristol Myers Squibb and Thermo Fisher Pharma Services, while a fifth drug maker recently completed a 'successful evaluation'. The five drug makers on the books represent a sales opportunity of between 60 to 80 units. At last count the company had 13 APAS devices in the field, with foundation client Astrazeneca accounting for nine of them. The company cites a 'pipeline' of 40 customers, representing upfront revenue of about $75 million and $15 million of recurring revenue. The APAS unit sells for US$350,000, but Clever Culture then derives ongoing income from an annual software licence of US$30,000 (rising to US$50,000 with the contact plate modality). There's also an annual hardware maintenance fee of $US15,000-25,000. The FDA approved APAS Independence in May 2019 and European regulators followed suit in September 2021. There's no snoozing at Compumedics Sleep and neurological testing house Compumedics (ASX:CMP) has reported record revenue of $51 million for the year to June 2025, up 4%. What's more, the company has returned to profitability, with underlying earnings of $3 million. Compumedics also reports record sales orders of $63.4 million, up 22%. The key driving force was the growth of the US sleep diagnostics arm, up 39% to $53 million. The company also affirmed current year guidance of revenue of at least $70 million and underlying earnings of around $9 million. 'This result reflects the step-change underway at Compumedics,' founder and executive chairman Dr David Burton says. "We are building a more predictable, higher-margin business model and seeing consistent revenue growth, expanding margins and meaningful traction in the US." Proteomics ain't horsing around In time for the spring racing season, Proteomics International Laboratories (ASX:PIQ) says its oxidative stress test Oxidx can detect muscle damage in thoroughbreds. As published in the peer-reviewed journal Veterinary Medicine and Science, the 'groundbreaking' results show Oxidx can identify and assess recovery from exercise-induced damage. The study was based on 34 nags. The company says up to 85% of thoroughbreds sustain at least one injury during their racing seasons, potentially because of undetected muscle injuries. 'Oxidative stress has been implicated in many disease and injury states, with levels often reflective of a person or animal's health condition.' Via its 66% owned OxiDx Pty Ltd, Proteomics plans to launch Oxidx locally in the current half. Proteomics has a commercialised diabetic kidney disease diagnosis and plans to launch an endometriosis assay locally in the current quarter. No pay, no worries says Pacific Edge Pacific Edge (ASX:PEB) reports resilient demand for its bladder cancer diagnostic in the US, despite authorities withdrawing reimbursement coverage. The Kiwi-based company said US June quarter test volumes declined 12% to 5717, relative to the March quarter. Asia Pacific volumes – including those derived here – rose 8.8% to 1183. The company attributed the decline mainly to customers moving to its Cxbladder Triage product, from the discontinued Cxbladder Detect. Cxbladder Triage tests accounted for 77% of total US assays, up from 22% in the March quarter. Pacific Edge also said it had held positive discussions with Novitas, its US Medicare gatekeeper, about reinstating coverage. This was 'based on evidence not considered in the review that led to the non-coverage decision.'

News.com.au
3 hours ago
- News.com.au
‘Hidden, scary problem': Counterfeit botox, fillers easy to order into Australia
A leading injectable cosmetics figure is seeing a 'scary' number of unlicensed operators pushing dangerous procedures. In 2023, Australia's legitimate injectable cosmetics industry was worth $4.1bn. Meanwhile, authorities receive about 100 complaints each year concerning non-surgical cosmetic procedures, levelled at medical practitioners, nurses, midwives, dentists, psychologists and Chinese medicine practitioners. Dr Vivek Eranki, a cosmetic medicine practitioner with national oversight, is raising the alarm after authorities seized two counterfeit batches of botulinum toxin – or botox – in recent months. 'This is more of a hidden problem, in that it is very easy for practitioners to pass it off as they are using a real product – but not documenting exactly what's been used,' Dr Eranki told NewsWire. Dr Eranki describes the black market injectors as very discreet and crafty about what they are saying is being injected. 'People can put in false information if they are trying to cover their tracks and this is what makes it so scary,' Dr Eranki said. 'We know there are fake products coming in and it is very easy to hide it.' This week, the national medicine regulator revealed two separate batches of counterfeit botox had been seized at the border in recent months. The vials were packaged to look like a genuine brand, but typos alerted authorities. The Therapeutic Goods Administration stressed the botox was purchased from an overseas website, and the duped manufacturer confirmed the batch numbers were illegitimate. Because they are investigating further, the TGA is unwilling to say where and when the boxes were seized, nor what type of establishment had ordered them. In a statement, a spokeswoman from the Australian Medical Association said people should use only qualified health practitioners, 'The AMA reminds Australians that all medical procedures, including cosmetic injections, carry risk and should only be performed by suitably qualified health practitioners,' the spokeswoman said. 'Anyone planning a procedure should ensure they understand the skills and qualifications of the person undertaking the procedure.' Dr Eranki said common sense was the key to avoiding shady injectors. 'Never go to somebody's house, never go to a hair salon to get your treatment done. Make sure that whoever's doing your treatment is adequately trained and qualified.' 'At the end of the day the governmental infrastructure, the regulators, the authorities can only do so much. At some point, common sense needs to take over. And I think that's where the solution lies.' In January, three Sydney women ended up in hospital with botulism infections, with one requiring treatment in the intensive care unit. The Health Care Complaints Commission issued a temporary, and then permanent, prohibition order against unregistered injector Norsafiza Binti Zakaria, who advertised her services using at least six different aliases. The Australian Health Practitioner Regulation Agency has conducted multiple raids on commercial and private residences across the country in recent months, seizing illegal injectables from unqualified practitioners. AHPRA received 360 complaints about non-surgical cosmetic procedures between September 2022 and March 2025. These notifications were made against medical practitioners, nurses, midwives, dentists, psychologists and Chinese medicine practitioners. ''If something doesn't feel right then patients should trust their gut and hit pause,' a spokesperson said. 'Patients should ensure that their injector is a registered health practitioner by asking for their registration number and looking them up on the national register of practitioners.'